Key pos­i­tive da­ta on month­ly HIV reg­i­men of­fer hope for pa­tients sad­dled with stan­dard dai­ly pills

HIV pa­tients have much to cheer about this week. Af­ter re­ports that a sec­ond HIV pa­tient has ex­pe­ri­enced sus­tained re­mis­sion fol­low­ing a bone mar­row trans­plant, a pair of drug­mak­ers on Thurs­day post­ed piv­otal da­ta that showed their month­ly in­jectable treat­ments worked as well as the stan­dard dai­ly three-drug cock­tail in sup­press­ing the virus that caus­es AIDS.

The in­jectable reg­i­men com­pris­ing two drugs — John­son & John­son’s $JNJ rilpivirine (sold as Edu­rant) and Vi­iV Health­care’s ex­per­i­men­tal treat­ment cabote­gravir — was test­ed in a two late-stage stud­ies in more than 1180 pa­tients al­to­geth­er. The to­tal dataset will be used to sub­mit ap­pli­ca­tions to mar­ket the in­jectable for­mu­la­tion to reg­u­la­tors lat­er this year, Vi­iV said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.